Some DBV Technologies (EPA:DBV) Shareholders Have Taken A Painful 83% Share Price Drop

DBV Technologies S.A. (EPA:DBV) shareholders will doubtless be very grateful to see the share price up 43% in the last month. But only the myopic could ignore the astounding decline over three years. The share price has sunk like a leaky ship, down 83% in that time. So it's about time shareholders saw some gains. But the more important question is whether the underlying business can justify a higher price still.

We really hope anyone holding through that price crash has a diversified portfolio. Even when you lose money, you don't have to lose the lesson.

Check out our latest analysis for DBV Technologies

DBV Technologies wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

In the last three years, DBV Technologies saw its revenue grow by 9.8% per year, compound. That's a fairly respectable growth rate. So it's hard to believe the share price decline of 44% per year is due to the revenue. It could be that the losses were much larger than expected. If you buy into companies that lose money then you always risk losing money yourself. Just don't lose the lesson.

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).

ENXTPA:DBV Income Statement May 12th 2020
ENXTPA:DBV Income Statement May 12th 2020

If you are thinking of buying or selling DBV Technologies stock, you should check out this FREE detailed report on its balance sheet.

Advertisement

A Different Perspective

We regret to report that DBV Technologies shareholders are down 32% for the year. Unfortunately, that's worse than the broader market decline of 11%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 24% over the last half decade. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For example, we've discovered 2 warning signs for DBV Technologies (1 is a bit concerning!) that you should be aware of before investing here.

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on FR exchanges.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

About ENXTPA:DBV

DBV Technologies

A clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France.

High growth potential with excellent balance sheet.

Advertisement

Weekly Picks

CE
Ceazar
CNXU logo
Ceazar on Conexeu Sciences ·

This small biotech is developing technology that could potentially change how tissue is rebuilt

Fair Value:US$25.3458.4% undervalued
53 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
IN
Investingwilly
MA logo
Investingwilly on Mastercard ·

Mastercard: The Best Dividend Stock You're Ignoring

Fair Value:US$75034.9% undervalued
8 users have followed this narrative
0 users have commented on this narrative
3 users have liked this narrative
TR
tripledub
INTU logo
tripledub on Intuit ·

A Wonderful Business at a Not-So-Wonderful Price

Fair Value:US$56053.9% undervalued
44 users have followed this narrative
1 users have commented on this narrative
26 users have liked this narrative
TA
Talos
HYFT logo
Talos on MindWalk Holdings ·

The Asymmetric TechBio Play: MindWalk Holdings and the Valuation Disconnect

Fair Value:US$8.2782.0% undervalued
11 users have followed this narrative
0 users have commented on this narrative
4 users have liked this narrative

Updated Narratives

HA
HarishPK
DOX logo
HarishPK on Amdocs ·

Why Amdocs is a high conviction Buy for me?

Fair Value:US$82.0336.2% undervalued
2 users have followed this narrative
1 users have commented on this narrative
0 users have liked this narrative
DE
Delphic
SMR logo
Delphic on NuScale Power ·

NuScale is Postioned For Long-Term Growth

Fair Value:US$10089.1% undervalued
10 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
TR
WMT logo
Treasury_Raccoon_w0gg on Walmart ·

Walmart's 'Other' Segment Will Power New Growth Beyond Retail

Fair Value:US$154.5822.7% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

MA
martinarauz
NU logo
martinarauz on Nu Holdings ·

Investment Analysis (May 2026)

Fair Value:US$22.7444.6% undervalued
67 users have followed this narrative
0 users have commented on this narrative
16 users have liked this narrative
HA
HarishPK
ADBE logo
HarishPK on Adobe ·

Adobe: A Probabilistic Case for Undervaluation

Fair Value:US$319.9638.3% undervalued
61 users have followed this narrative
9 users have commented on this narrative
18 users have liked this narrative
HE
HedgeY
ASTS logo
HedgeY on AST SpaceMobile ·

AST SpaceMobile: The Boldest Direct-to-Cell Bet in Public Markets

Fair Value:US$17057.1% undervalued
51 users have followed this narrative
0 users have commented on this narrative
13 users have liked this narrative